Manuel Aivado
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Manuel Aivado has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Akos Czibere
University Hospital Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Germany
3 shared publications Aristoteles A.N. Giagounidis
2 shared publications- Luiz Fernando Zerbini
International Centre for Genetic Engineering and Biotechnology (ICGEB), Weirner & Beit Building, Anzio Rd, Observatory, Cape Town 7935, South Africa
2 shared publications Rainer Haas
2 shared publications- Rainer Haas
Department of Hematology, Immunology, and Clinical Immunology, Heinrich Heine University Düsseldorf, University Hospital Düsseldorf
2 shared publications - Towia A. Libermann
Harvard Medical School, Boston, MA
2 shared publications
Latest Publications
- 1 January 2009
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 50 (6) , 1043-1046
Meningioma 1 gene is differentially expressed in CD34 positive cells from bone marrow of patients with myelodysplastic syndromes with the highest expression in refractory anemia with excess of blasts and secondary acute myeloid leukemia
- 1 January 2009
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 50 (6) , 1043-1046
Meningioma 1 gene is differentially expressed in CD34 positive cells from bone marrow of patients with myelodysplastic syndromes with the highest expression in refractory anemia with excess of blasts and secondary acute myeloid leukemia
- Open Access
- 28 September 2006
- Published by Wiley in British Journal of Haematology
- Vol. 135 (3) , 355-357
Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS
- 28 September 2006
- Published by Wiley in British Journal of Haematology
- Vol. 135 (3) , 355-357
Open AccessExisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS
- 1 July 2006
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 37 (1) , 40-45
X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns
- 1 July 2006
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 37 (1) , 40-45
X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns
- 8 April 2005
- Published by Taylor & Francis in Cell Cycle
- Vol. 4 (6) , 812-817
The Nonsteroidal Anti-Inflammatory Drug Exisulind Selectively Induces Apoptosis via JNK in Secondary Acute Myeloid Leukemia after Myelodysplastic Syndrome
Treatment of patients suffering from myelodysplastic syndromes and secondary acute myeloid leukemia after MDS is often unsuccessful. Pro-apoptosis with arsenic trioxide has recently been proposed as a novel therapeutic approach. Exisulind is another potentially pro-apoptotic agent, and therefore, we investigated its influence on proliferation, differentiation, cell cycle and apoptosis in two sAML/MDS cell lines, one de-novo AML cell line and healthy CD34+ bone marrow cells. Treatment of sAML/MDS cells with Exisulind clearly inhibited colony formation in the CFU-assays. Interestingly, Exisulind did not alter the percentages of sAML/MDS cells in G1-, G2-, M- or S-phase, but reduced proliferation and induced apoptosis in this cell type. Exisulind had no effect on de-novo AML or normal CD34+ cells. We detected increased c-Jun NH2-terminal kinase activity in sAML/MDS cells treated with Exisulind. Adding a specific JNK-inhibitor to Exisulind-treated sAML/MDS cells partly abrogated apoptosis, thus proving that Exisulind-mediated apoptosis in sAML/MDS cells is dependent on JNK activation. We conclude that JNK is one mediator of apoptosis in sAML/MDS cells treated with Exisulind. Moreover, our data strongly suggests to explore the potential use of Exisulind as a novel, pro-apoptotic therapy for patients with MDS and sAML/MDS.
- 8 April 2005
- Published by Taylor & Francis in Cell Cycle
- Vol. 4 (6) , 812-817
The Nonsteroidal Anti-Inflammatory Drug Exisulind Selectively Induces Apoptosis via JNK in Secondary Acute Myeloid Leukemia after Myelodysplastic Syndrome
Treatment of patients suffering from myelodysplastic syndromes and secondary acute myeloid leukemia after MDS is often unsuccessful. Pro-apoptosis with arsenic trioxide has recently been proposed as a novel therapeutic approach. Exisulind is another potentially pro-apoptotic agent, and therefore, we investigated its influence on proliferation, differentiation, cell cycle and apoptosis in two sAML/MDS cell lines, one de-novo AML cell line and healthy CD34+ bone marrow cells. Treatment of sAML/MDS cells with Exisulind clearly inhibited colony formation in the CFU-assays. Interestingly, Exisulind did not alter the percentages of sAML/MDS cells in G1-, G2-, M- or S-phase, but reduced proliferation and induced apoptosis in this cell type. Exisulind had no effect on de-novo AML or normal CD34+ cells. We detected increased c-Jun NH2-terminal kinase activity in sAML/MDS cells treated with Exisulind. Adding a specific JNK-inhibitor to Exisulind-treated sAML/MDS cells partly abrogated apoptosis, thus proving that Exisulind-mediated apoptosis in sAML/MDS cells is dependent on JNK activation. We conclude that JNK is one mediator of apoptosis in sAML/MDS cells treated with Exisulind. Moreover, our data strongly suggests to explore the potential use of Exisulind as a novel, pro-apoptotic therapy for patients with MDS and sAML/MDS.